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Introduction
FA (Fanconi anemia) is a disease characterized by developmental 
abnormalities, bone marrow failure and cancer predisposition. At 
the cellular level, FA is characterized by extreme sensitivity to 
ICLs (interstrand crosslinks). When a replication fork encoun-
ters an ICL, unwinding cannot occur, and a host of replication 
proteins, nucleases, translesion polymerases and recombination 
proteins constitute a multigene repair pathway, the FA/BRCA 
(breast cancer) pathway, to resolve the block (Fig. S1). The FA/
BRCA pathway is fundamental, however, not just to repair of 
ICLs, but also to the repair of damage elicited by DNA replica-
tion fork stalling due to numerous endogenous and exogenous 
insults.1-7
The recombination step in the FA/BRCA pathway requires 
resection of duplex ends, and is poorly characterized compared 
with other steps.8-11 Resection of DSBs was first delineated in 
yeast, Saccharomyces cerevisiae.12 After the induction of a DSB, 
the MRX (Mre11, Rad50, Xrs2) complex and Sae2 (MRN 
and CtIP in human) can carry out a limited resection reaction 
of about 100 bp. A second, long-range resection reaction pro-
vides the 3' ssDNA overhang that binds RPA and RAD51, the 
DNA strand exchange protein, which are important for HDR 
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(homology-directed repair) and checkpoint signaling. In one 
long-range resection machine, EXO1 (exonuclease 1) degrades 
the 5' strands, but is redundant with a second pathway involving 
a complex of Sgs1 3'–5' DNA helicase and the Dna2 nuclease. It is 
not clear what directs the division of labor between the two resec-
tion pathways. Understanding resection in the FA/BRCA path-
way, specifically, is important, because end resection enhances the 
chromatin association of the key regulatory complex, FANCD2/
FANCI, at DSBs and directs the choice of pathway in repair, 
either error free HDR or NHEJ (nonhomologous end-joining), 
which can lead to deleterious rearrangements (Fig. S1). MRN 
(Mre11, Rad50, Nbs1) and CtIP have been implicated in FA/
BRCA short-range resection reaction,1,3 but long-range resection 
may also occur,9 and the long-range apparatus, if any, has not 
been identified.
DNA2 or EXO1 are good candidates for the predicted long-
range resection nucleases. Biochemical reconstitution experi-
ments by our lab and others define at least three DSB long-range 
resection pathways in human cells.13,14 In one mechanism, BLM 
helicase and DNA2 nuclease resect DNA; in a second path-
way, BLM directly stimulates the 5'–3' nucleolytic activity of 
EXO1;13,14 in the third pathway DNA2, EXO1 and BLM coop-
erate in resection.14 In vivo, DNA2 deficiency leads to partial 
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of aberrant intermediates with double-stranded ends (reversed 
forks).22 In addition, CPT causes DNA damage by stabilizing 
topoisomerase I-DNA adducts and preventing DNA ligation after 
cleavage, leading to DSBs upon subsequent DNA replication. 
Key proteins involved in HDR, such as the MRN/CtIP complex, 
are important in the repair of the latter type of CPT-induced 
damage.23-25 The MRN complex and RPA colocalize at sites of 
DNA damage after treatment with CPT,24 and cells defective in 
resection are sensitive to CPT.16 It is not possible, as was done for 
studying synchronously induced, site-specific DSBs in yeast, to 
directly measure resection in human cells using hybridization to 
specific probes. We therefore used several indirect methods from 
which the 3' ssDNA produced by resection can be inferred.26-28 
We first examined the phosphorylation status of RPA, a hetero-
trimeric ssDNA-binding complex comprised of RPA1, RPA2 and 
RPA3, which binds the resected single-stranded DNA. ssDNA-
bound RPA2 is phosphorylated by the ATR checkpoint kinase 
at serine 3329 and then by the PI3 kinase, DNA-PKcs, at serine 4 
and 830 in response to DNA DSB damage. Therefore, impaired 
hyperphosphorylation of RPA2 can be used as a surrogate for 
reduced production of ssDNA by resection.16 Cells with DNA2 
and/or EXO1 depletion were treated with CPT and extracts pre-
pared. Immunoblotting experiments using antibodies that recog-
nize RPA2-pS4/S8 and RPA2-pS33 revealed that in the presence 
of DNA damage, RPA2 was robustly phosphorylated in SCR 
(scrambled) controls. The DNA2/EXO1 doubly depleted cells 
had markedly diminished levels of RPA2-pS4/S8 and pS33 com-
pared with the SCR control and to singly depleted DNA2 and 
EXO1 (Fig. 1B). Notably, in the DNA2 depleted cells, there was 
a modest but reproducible increase in RPA phosphorylation even 
in the absence of CPT (Fig. 1B, lanes 2 and 4 and see also Fig. 2), 
which we have shown elsewhere is likely due to endogenous DNA 
damage occurring in the absence of DNA2.18
We confirmed that the diminished levels of RPA2-pS4/S8 
phosphorylation after CPT were not due to off-target shRNA 
effects in two ways. First, we repeated the experiments with 
another shRNA, shDNA2', described previously.17,18 Interestingly, 
shDNA2' significantly reduced RPA phosphorylation even in the 
presence of EXO1 (Fig. 1C; Fig. S2), confirming our previous 
in vitro work and another recent report.14,15 This appeared to be 
due to a greater reduction in levels of DNA2 by shDNA2' than 
shDNA2 (Fig. S2 and not shown). Second, we rescued RPA 
phosphorylation by ectopically expressing RNAi-resistant DNA2 
(compare Fig. 1C and D), also as we described previously.17,18 
Figure S2 verifies the efficiency of expression of RNAi-resistant 
DNA2 cDNA.
Role of DNA2 resection in repair of interstrand crosslinks. 
It is likely that DNA2 and EXO1 function in conjunction with 
other proteins, such as components of the FA/BRCA network. 
Cisplatin causes ICLs between two opposite guanines, which 
physically block converging replication forks. This lesion is 
thought to be converted to a DSB during replication-associated 
ICL removal by the FA/BRCA pathway (Fig. S1). Mechanistic 
studies have demonstrated a role for at least 700 bp of resection 
and RAD51-dependent strand invasion into the sister chromatid 
in replication-coupled repair of a single, site-specific cisplatin ICL 
defects in resection,15 and BLM and EXO1 identify two redun-
dant DSB repair pathways.16 Two critical questions are to what 
extent are the BLM/DNA2 and EXO1 pathways redundant, 
complementary or cooperative and how do these proteins protect 
stressed DNA replication forks.
DNA2 is perhaps of greatest interest with respect to resection 
of DSBs occurring during replication, because it is an intrinsic 
replication fork protein.15,17,18 Human DNA2, like yeast DNA2, 
functions in both mitochondria and nuclei.17,19,20 DNA2 deple-
tion in human cells results in DNA damage, as evidenced by 
increased chromosome breakage, interchromosomal bridges and 
micronuclei, induction of γH2AX repair foci and induction of 
the ATR-dependent S phase checkpoint, resulting in a severe G
2
 
delay of the cell cycle.17,18 The putative role of DNA2 in DNA 
replication is in processing of Okazaki fragments (or in repair of 
faulty processing). Breaks, however, did not accumulate during 
ongoing replication after silencing human DNA2; nor was fork 
slowing observed.18 Instead, origin firing is suppressed.18 Origin 
suppression is known to lead to the instability of common DNA 
fragile sites, long, origin-poor chromosome domains that may 
experience increased stalling or incomplete or delayed resolution 
of stalled forks by forks converging from distant origins.21 This 
suggested to us that DNA2 might also be required both for rep-
lication and for a post-replicative DNA repair step in replication 
completion. We now demonstrate that DNA replication-linked 
DNA damage accumulates when DNA2 is depleted, at least in 
part due to defects in repair. We show that DNA2 is involved in 
resection of DSBs occurring during replication stress and that 
EXO1 is redundant with DNA2. DNA2 and EXO1 also redun-
dantly regulate DSB repair pathway choice by inhibiting induc-
tion of phosphorylation of the NHEJ-related kinase DNA-PKcs. 
Most important, in beginning to delineate between the roles of 
DNA2 and EXO1 in multiple DSB repair pathways, we pres-
ent evidence that DNA2 plays a prominent role in coordinating 
resection and checkpoint activation in the FA/BRCA pathway 
of ICL repair. Given its constitutive role in DNA replication, 
DNA2 may constitute a direct link between replication fork fail-
ure and HDR.
Results
DNA2 and EXO1 nucleases play redundant roles in resection 
of replication-associated DSBs. To study the respective roles of 
DNA2 and EXO1 in replication-linked DSB repair in vivo, we 
either singly or simultaneously depleted DNA2 and EXO1, using 
shDNA2 and siEXO1, respectively, in U2OS cells. We achieved 
a depletion efficiency of at least 80% for each of the targeted 
mRNAs (Fig. 1A). (Neither DNA2 nor EXO1 protein, very low 
abundance proteins, are detectable on Westerns with available 
antibodies). The cell cycle distribution of such deletions shows 
an increased S and G
2
 population, the portion of the cell cycle 
we wish to monitor.18 We then investigated resection of CPT 
(camptothecin)-induced damage in the depleted cells. CPT 
inhibits DNA replication by inhibition of topoisomerase events 
critical for maintaining normal topological tension during elon-
gation. Such inhibition has been proposed to underlie formation 
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(compare Fig. 2A, lane 6 and lane 8). Similar results were 
obtained with a second shRNA, shDNA2' (Fig. 2B and C); 
and expressing wild-type, RNAi-resistant DNA2 rescued the 
DNA2 depletion defects in cisplatin-treated cells. (The results 
for single knockdowns show some variability from experiment to 
experiment, but the double knockdowns are consistently defec-
tive). RPA phosphorylation was also diminished when we used a 
second shRNA, shDNA2' (Fig. 2B and C; Fig. S2), ruling out 
in Xenopus extracts.9-11 However, the long-range nuclease(s), if 
any, involved in resection have not been identified.
When DNA2- or DNA2 and EXO1-depleted cells were 
treated with cisplatin, RPA2-pS33 was drastically reduced in the 
double depletion compared with controls (Fig. 2A), as with CPT 
(Fig. 1). Interestingly, when exposed to cisplatin, DNA2-depleted 
cells, but not EXO1-depletes, had a reduction in RPA2-pS33 
equivalent to that seen in the DNA2/EXO1 co-depleted cells 
Figure 1. DNA2 and eXO1 are required for resection at CPT-induced damage. (A) Targeting of DNA2 and/or eXO1 with shDNA2 and eXO1 siRNA 
resulted in at least 80% reduction of the respective mRNA levels. (B) After exposure to CPT (1 μM, 1 h), phosphorylation of RPA2 S4/S8, S33 and CHK1 
S345 is reduced in DNA2/eXO1-depleted U2OS cells. (C) A second shRNA targeting DNA2 (pReSQ shDNA2’) used together with eXO1 siRNA for double 
depletion, recapitulated results shown in (B). (D) Retrovirally expressed RNAi-resistant DNA2 restored RPA phosphorylation in cells depleted using 
shDNA2’ and eXO1 siRNA. Chk1 is also shown in addition to RPA (Figure presents an image with intervening lanes removed for clarity.). experiments 
were performed at least twice and representative results are shown. See experimental Procedures for details.
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singly-depleted cells, but not in EXO1-depleted cells, correlates 
with increased sensitivity of DNA2 depletions to chronic or acute 
treatment with cisplatin and physical interaction between DNA2 
and FANCD2 (see below). Thus, we propose that DNA2 and 
EXO1 also participate in ICL repair during DNA replication, 
even though the initiating lesion is somewhat different from that 
encountered by CPT (Fig. 1).
off-target effects. [The reduced RPA-pS33 did not seem to signif-
icantly affect RPA2-pS4/S8 (Fig. 2A)]. This raises the intrigu-
ing question of whether there is a threshold phosphorylation at 
S33 that can “prime” the hyperphosphorylation of pS4/S8.31 
Alternatively, DNA2 may have another role in repair of ICL dam-
age that more directly affects the phosphorylation of RPA2-S33. 
The ICL-induced reduction in RPA2-pS33 observed in DNA2 
Figure 2. DNA2 and eXO1 are required for resection at ICL-induced damage. (A) shDNA2/eXO1 siRNA-treated cells exposed to cisplatin (15 μM, 24 h) 
show reduced phosphorylation of RPA2 S4/S8, S33 and Chk1 S345 compared with shSCR-treated cells. (B) shDNA2’/eXO1 siRNA-treated cells ex-
posed to cisplatin (15 μM, 24 h) show reduced phosphorylation of RPA2 S4/S8, S33 and Chk1 S345 compared with shSCR-treated cells and ectopically 
expressed, RNAi-resistant DNA2 restored RPA and Chk1 phosphorylation in depleted U2OS cells (C). CDDP, cisplatin. experiments were performed at 
least twice. See also Figure S2. See experimental Procedures for details.
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cells, had significantly fewer RPA foci (10%) (Fig. 3B). Control 
cells with CtIP depletion had levels of RPA foci (6%) similar to 
those of the double depletion.
The RPA complex that binds to ssDNA during resection is 
replaced by RAD51, which forms a dynamic nucleoprotein fila-
ment involved in strand invasion. A reduction in RAD51 foci 
would also suggest impaired resection. We examined RAD51 
focus formation after exposure to cisplatin or CPT in DNA2 
and/or EXO1-depleted cells. In response to CPT, DNA2/EXO1 
doubly depleted cells had 33% fewer foci than the SCR control, 
and 25% and 29% fewer foci than EXO1 or DNA2 single deple-
tions, respectively (Fig. 3D). We also saw a marked reduction in 
RAD51 foci in cisplatin treated DNA2-depleted cells compared 
with the SCR control (Fig. 3D). Instructively, RPA2-pS4/S8 is 
essential for recruitment of RAD51 to ssDNA after exposure to 
hydroxyurea, which stalls replication forks.36 The smaller reduc-
tion in RAD51 foci than in BrdU or RPA foci, Figure 3A–C, 
most likely reflects that, in the absence of DNA2, some RAD51 
continues to be recruited to the stalled forks to protect the repli-
cation fork from collapse before any break and need for resection 
occurs. We have demonstrated that DNA2 deficiency in itself 
induces replication fork stress.17,18 The role of RAD51 in fork 
protection rather than fork repair has been reported recently in 
Xenopus and human.37-39 In fact, RAD51 is recruited to ICLs 
before the initial incisions, that is, before its role in repair of the 
broken sister chromatid.9 Interpretation of the RAD51 data illus-
trates the unique challenges imposed by working with a gene 
involved both in constitutive DNA replication and in repair of 
stressed replication forks.
DNA2- and EXO1-depleted cells accumulate unrepaired 
Cisplatin and CPT-induced breaks. To verify a defect in DSB 
repair, we examined whether the cells accumulated broken DNA 
in two ways. First, we monitored accumulation of CPT-induced 
DSBs using PFGE (pulse field gel electrophoresis) after DNA2 
and/or EXO1 depletion. Cells were treated with DNA-PK 
inhibitor NU7441 to reduce potentially compensating repair by 
NHEJ, and exposed to CPT for 2 h. Even cells singly depleted of 
DNA2 or EXO1 showed accumulation of DSBs compared with 
the scrambled control. The DNA2 and EXO1 doubly depleted 
cells, however, had even higher levels of unrepaired DSBs than 
either of the single depletions (Fig. 4A, typical gel representa-
tive of four biological replicates). This again suggests synergy 
between DNA2 and EXO1 depletions. As a second demonstra-
tion of increased DSBs, we monitored the frequency of gaps in 
sister chromatids, using a chromosomal aberration assay, and 
found an increase in gaps/DSBs in the double depletes and in 
DNA2-depleted cells treated with cisplatin or CPT compared 
with untreated cells (Fig. 4B). (We attribute the apparent differ-
ence in level of CPT-induced breaks in the EXO1-depletes moni-
tored by PFGE in Fig. 4A compared with Fig. 4B to the absence 
of NHEJ inhibitor in the metaphase spread experiments).
DNA2 repair pathways intersect with the FA/BRCA path-
way: DNA2 interaction with FANCD2. In yeast, one member 
of the FA/BRCA family that is conserved is FANCM/Mph1. 
High-copy expression of Mph1 suppresses the lethality of a 
yeast dna2 helicase-dead mutant, and purified Mph1 stimulates 
Failure to hyperactivate the ATR and Chk1 DNA dam-
age response in DNA2- and/or EXO1-depleted cells treated 
with Cisplatin and other replication-coupled DNA damaging 
agents. The RPA-coated ssDNA overhangs generated by resec-
tion are crucial for ATR checkpoint kinase recruitment and full 
activation.27,32-34 Once activated, ATR phosphorylates the effec-
tor checkpoint kinase, Chk1, on S345 to promote cell cycle delay 
and repair. Thus, the appearance of Chk1-pS345 provides both 
an additional readout for resection and an indirect measure of 
ATR activation. DNA2 and/or EXO1 were depleted from U2OS 
cells, and cells were exposed to cisplatin or CPT, as above. With 
cisplatin, consistent Chk1-S345 reduction was seen only with the 
double-depletion (Fig. 2A and B). Phosphorylation could be res-
cued by expression of RNAi-resistant DNA2 (Fig. 2C, lane 4 
and Fig. S2B).
With CPT, we consistently observed a greater reduction in 
Chk1-pS345 phosphorylation in doubly DNA2/EXO1-depleted 
cells than in either single depletion (Fig. 1B). The reduction in 
doubly depleted cells was equivalent to that observed with CtIP 
depletion, further verifying that this readout correlates with 
a resection defect.16 In the presence of RNAi-resistant DNA2, 
we observed no reduction in Chk1 phosphorylation in response 
to CPT (Fig. 1D). We also note that in the absence of exog-
enous damage, there is a modest increase in RPA2-pS4/S8 and 
Chk1-pS345 (Figs. 1 and 2), again consistent with our recent 
demonstration that there is endogenous DNA replication dam-
age due to DNA2 deficiency and activation of the DNA damage 
response.18 We conclude, that DNA2 and EXO1 participate in 
partially redundant pathways of resection in response to cisplatin 
or CPT, though DNA2 appears to have a greater role than EXO1 
or may coordinate with EXO1.
To more directly demonstrate a role for DNA2 and EXO1 
in ssDNA generation, we monitored ssDNA accumulation using 
BrdU (5-bromodeoxyuridine) antibody. BrdU is incorporated 
into double-stranded DNA but is only detectable with anti-BrdU 
antibody in regions of single-stranded DNA. Cells with single or 
double depletion of DNA2 and EXO1 were cultured in BrdU for 
several generations to uniformly label chromosomes, be exposed 
to CPT and be stained for BrdU foci without denaturation. CtIP 
depletion was used as a positive control.25,35 We observed a signifi-
cant reduction in BrdU focus formation in cells having simulta-
neous DNA2 and EXO1 depletion (6%) compared with DNA2 
or EXO1 depletion alone (19% and 29%, respectively), similar to 
the reduction seen in CtIP-depleted cells (Fig. 3A).25,35 The single 
DNA2- or EXO1-depleted cells were also slightly impaired com-
pared with the SCR-treated controls, which showed 36% of cells 
with BrdU foci, suggesting partially independent repair pathways 
that cannot compensate for each other’s absence.
We next monitored RPA2-pS4/S8 foci.16,35 DNA2 and/or 
EXO1-depleted cells were exposed to CPT and immunostained 
for RPA2-pS4/S8 foci and for γH2AX, a marker of chromatin at 
DSBs, to identify cells that had undergone damage. The number 
of cells with RPA2-pS4/S8 foci in γH2AX-positive cells was then 
determined. DNA2 or EXO1-depleted cells had reduced levels 
of RPA focus formation (26% and 23%, respectively) compared 
with the SCR cells (37%). DNA2 and EXO1 double depleted 
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Figure 3. For figure legend, see page 3989.
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likely functions downstream of (or in parallel with) FANCD2 
(Fig. 5C).
Depletion of DNA2 leads to a reduction in SSA (single-
strand annealing), a specific subpathway of HDR. The FA 
pathway components have been implicated in replication-cou-
pled HDR repair of preformed DSBs previously.42 To deter-
mine if DNA2, like other FA proteins, was involved in HDR 
at preformed DSBs, we used a reporter, DR-GFP, composed of 
direct repeats of two mutated GFP genes.43 One repeat is inac-
tivated by insertion of an I-Scel recognition site and the other 
repeat is a GFP fragment (Fig. 5D, insert from ref. 44). Upon 
induction of I-SceI endonuclease, repair of the I-SceI DSB by 
HDR (gene conversion) leads to reconstitution of GFP, allow-
ing the efficiency of HDR to be quantified by flow cytometry. 
Surprisingly, GFP+ cells increased, rather than decreased, in cells 
treated with shDNA2 (Fig. 5D). Since DNA2 is involved in 
DNA2 nuclease.40 This suggested human DNA2 might function 
in the FA/BRCA pathway, and we next addressed whether DNA2 
and EXO1 act in conjunction with any of the human FA path-
way factors. FANCD2 is a central component of the FA/BRCA 
pathway, and after monoubiquitylation is essential, in complex 
with FANCI, to induce the initial incisions and for the sequen-
tial TLS, NER and HDR steps in ICL removal (Fig. S1). Also, 
like DNA2, it is constitutively associated with replication forks.7 
We first asked if DNA2 interacts with FANCD2. We find that 
DNA2 and FANCD2 show surprisingly robust interaction, given 
the low levels of DNA2 present in nuclei. FANCD2 co-immuno-
precipitates with endogenous DNA2 in extracts incubated with 
α-DNA2. In the reverse experiment, we failed to find DNA2 
in FANCD2 immunoprecipitates (Fig. 5A). However, DNA2 
is expressed at very low levels and a large fraction is mitochon-
drial rather than nuclear. Therefore, we overexpressed DNA2 in 
HEK293T cells. In this case, FANCD2 was able to co-immuno-
precipitate DNA2 (Fig. 5A, lower panel). We further confirmed 
the DNA2/FANCD2 interaction by adding purified FLAG-
DNA2 to extracts expressing endogenous levels of FANCD2 and 
demonstrating that the purified DNA2 protein co-immunopre-
cipitated with FANCD2 using α-FANCD2 antibody (Fig. 5A). 
Note that Figure 5A, top right, serves as the negative control for 
the coimmunoprecipitation in the lower panels. Since we have 
shown that DNA2 coimmunoprecipitates with And1, a replica-
tion fork protein, this DNA2/FANCD2 interaction may imply 
that they interact at replication forks.17,18
We next determined whether the interaction was likely due 
to protein/protein interaction by repeating the IPs in extracts 
treated with DNaseI. We also monitored interaction in the 
presence of ICL damage. As shown in Figure 5C, DNA2 and 
FANCD2 interact in the absence of DNA, suggesting protein/
protein interaction. Interestingly, when cells were treated with 
cisplatin, we saw interaction of DNA2, with both ubiquitylated 
and unmodified FANCD2. In addition, we noticed that a faint 
band always detected in the DNA2 IPs with DNA2 antibody 
was significantly increased after ICL damage, suggesting that 
DNA2 is modified upon ICL induction, as it is in yeast during 
HU treatment.41
To determine if DNA2 was required to induce FANCD2 ubiq-
uitylation, we determined whether FANCD2 was ubiquitylated 
in DNA2-depleted cells with ICL damage. DNA2 depletion did 
not reduce FANCD2 monoubiquitylation after treatment of cells 
with either cisplatin or with mitomycin C, another ICL-inducing 
agent. This implies that DNA2 is not needed for FANCD2 ubiq-
uitylation and, given that the two proteins interact, that DNA2 
Figure 3 (See opposite page). Formation of DNA damage foci is compromised after the depletion of DNA2/eXO1. Left panels are representative 
immunofluorescence images of BrdU, RPA and RAD51 foci and right panels are quantification of the cells shown on the left panel. (A) After exposure 
to CPT, DNA2/eXO1 U2OS-depleted cells have significantly fewer single-stranded BrdU foci compared with DNA2 or eXO1 single depletion. Cells 
with single or double depletion of DNA2 and/or eXO1 were cultured in BrdU, exposed to CPT (1 μM, 1 h) and stained with α-BrdU antibodies without 
denaturation. (B) After exposure to CPT (1 μM, 1 h), phospho-RPA2 S4/S8 foci are significantly less in DNA2/eXO1-depleted cells compared with DNA2 
or eXO1 depletion. (C) RAD51 foci are significantly diminished in DNA2/eXO1-depleted cells compared with DNA2 or eXO1 depletion after exposure to 
CPT (1 μM, 1 h). (D) After exposure to cisplatin (15 μM, 24 h), DNA2-depleted cells have reduced RAD51 foci formation. error bars indicate mean ± SeM 
for n = 3 independent experiments and *p < 0.05, **p < 0.01. Comparisons were also made with CtIP, as a control, but were not shown on the graph 
for clarity. Statistical analyses were done using an unpaired two-tailed t-test. At least 100 cells were counted for each independent experiment. See 
experimental Procedures for details.
Figure 4. DNA2/eXO1-depleted U2OS cells accumulate DSBs and 
broken chromosomes after CPT or cisplatin replication inhibition. (A) 
Pulse-field gel electrophoresis shows markedly higher amounts of unre-
paired DNA in DNA2/eXO1-depleted cells than in the DNA2 or eXO1-
depleted cells. (B) After the simultaneous depletion of DNA2 and eXO1, 
the number of breaks per metaphase spread observed in the absence 
of DNA damage (DMSO) increases upon exposure to cisplatin or to CPT. 
At least 100 cells were counted in each independent experiment. See 
experimental Procedures and Supplemental Materials for details. CDDP, 
cisplatin.
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Figure 5. DNA2 physically interacts with and functions downstream of FANCD2 and participates in SSA in vivo. (A) In U2OS cells, antibody against 
endogenous DNA2 coimmunoprecipitates FANCD2, but antibody against FANCD2 does not coimmunoprecipitate detectable amounts of DNA2 (top 
panel). When DNA2 is overexpressed or recombinant DNA2 added to the whole-cell extract, however, DNA2 is detectable in the FANCD2 immunopre-
cipitate (bottom panel). Whole-cell extracts were prepared from asynchronous HeK293T cells transfected with pcDNA3.1-DNA2–6His-4Myc. (B) DNA2 
was overexpressed in HeK293T cells with or without cisplatin treatment. Lysates were incubated in the presence of DNaseI59 and immunoprecipitation 
performed with FANCD2 antibody. (C) FANCD2 monoubiquitylation was unaffected in DNA2-depleted cells exposed to cisplatin or MMC (mitomy-
cin C). (D) Top panel is a diagram of the U2OS DR-GFP reporter used to examine HDR after I-SceI expression. DNA2 depletion caused an increase in 
GFP+ cells. (E) Top panel is a diagram of the U2OS SA-GFP reporter used to examine SSA after I-SceI expression. DNA2-depleted cells had a significant 
decrease in SSA. (F) Depletion of DNA2 in FANCD2-/- does not affect the level of HDR. HDR was measured in FANCD2-/- alone and in FANCD2-/- after 
shDNA2 knockdown, i.e., cells doubly deficient in FANCD2 and DNA2 using the DR-GFP assay.
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experiments and interaction of DNA2 with FANCD2 sug-
gested that DNA2 might mediate interaction between HDR 
and the FA/BRCA pathway. Genetic interaction with compo-
nents of the FA pathway during a DNA damage response is 
another approach to verify this. We were interested in whether 
silencing of human DNA2 and/or EXO1 led to hypersensitiv-
ity to ICLs, if there was synergy between DNA2/EXO1 deple-
tion and mutants in the FA/BRCA pathway, and if cells with 
silenced DNA2/EXO1 were sensitive to additional agents that 
cause replication stress.
First, we studied cisplatin sensitivity. SnmB1/Apollo, like its 
yeast Pso2 ortholog, is a 5' nuclease implicated in formation (or 
resection) of DSBs occurring during ICL repair.3 Although yeast 
pso2 mutants are only mildly sensitive to cisplatin, we observed 
that a pso2 dna2–1 double mutant was more sensitive to cisplatin 
long-range resection, we reasoned that the increase 
in GFP positive cells could be explained if DNA2 
depletion reduced a subpathway of HDR that 
competes with gene conversion, called SSA (single-
strand annealing).44 In SSA, DSBs are resected 
until regions of microhomology flanking the DSB 
are exposed and anneal to each other, creating a 
deletion of intervening DNA when joining occurs. 
SSA would result in a deletion of GFP and thus 
oppose gene conversion in the DR-GFP reporter 
assay. If DNA2 participated in SSA resection, then 
silencing of DNA2 might increase HDR. When 
we used a reporter that measures reconstitution of 
the GFP gene by SSA (Fig. 5E), we found a signifi-
cant decrease in SSA in the shDNA2-treated cells. 
Instructively, other FA/BRCA mutants, notably 
FANCA- and FANCD2-deficient cells, similarly 
have reduced SSA (Nakanishi, 2005). The stim-
ulation of SSA by DNA2 also suggests a role for 
DNA2 in resection upstream of BRCA2, impor-
tant for loading of RAD51, since BRCA2 inhib-
its SSA.45 We conclude that DNA2 is required for 
HDR, supporting recent studies by others.15
We also analyzed HDR in cells lacking both 
DNA2 and FANCD2 using a GFP assay similar 
to that described above. As reported previously, 
FANCD2-deficient PD20 cells are mildly defec-
tive in HDR.45 Depletion of DNA2 in PD20 cells 
does not affect the level of HDR (Fig. 5F). Since 
the phenotype of the double deplete is similar to 
FANCD2 deficiency and not to DNA2 deficiency 
(in U2OS cells), this suggests that DNA2 func-
tions downstream of FANCD2.
Resection represses induction of the NHEJ 
pathway. When the HDR pathway is compro-
mised, the NHEJ pathway is capable of DNA 
repair during S/G
2
-phase.46 DNA-PKcs is the 
protein kinase responsible for signaling during 
NHEJ. We hypothesized that NHEJ and, there-
fore, DNA-PKcs autophosphorylation would 
also be increased in DNA2/EXO1-depleted cells 
under replication stress. We used phospho-specific antibodies to 
examine DNA-PKcs autophosphorylation at S2056 and found a 
markedly increased signal in the double DNA2/EXO1-depleted 
compared with the singly depleted cells (Fig. 6A). We conclude 
that long-range resection is needed to block activation of NHEJ 
and short range is not sufficient. Interestingly, in cisplatin-treated 
cells, we did not observe an increase in DNA-PKcs phosphoryla-
tion (Fig. 6B). This could be explained by the previous dem-
onstration that FANCD2 inhibits the appearance of DNA-PKcs 
pS2056 foci in mitomycin C-treated cells.47 In keeping with 
this, we demonstrated DNA-PKcs phosphorylation in cisplatin-
treated PD20 cells and inhibition of phosphorylation in PD20 
cells complemented by FANCD2 (Fig. 6C).
DNA2 and EXO1 suppress genome instability due to 
Cisplatin, CPT or MMS treatment. The results of the cisplatin 
Figure 6. The depletion of DNA2/eXO1 increases phosphorylation of DNA-PKcs after 
CPT but does not after Cisplatin treatment. (A) Cells treated with CPT (1 mM, 1 h) showed 
extensive phosphorylation of DNA-PKcs. (B) Cells treated with cisplatin (15 μM, 24 h) 
showed no hyperphosphorylation of DNA-PKcs S2056. (C) In PD20 cells lacking FANCD2, 
DNA-PKcs S2056 is hyperphosphorylated after exposure to cisplatin (left) and expres-
sion of wild-type FANCD2 in PD20 cells inhibits the hyperphosphorylation (right), as 
proposed in the text. See experimental Procedures for details. CDDP, cisplatin.
3992 Cell Cycle Volume 11 Issue 21
to emphasize S phase repair (Fig. 7A). This level of sensitivity 
is significant and is similar, for instance, to the sensitivity to 
CPT demonstrated for CtIP depletion.48 The synergy between 
the DNA2 and EXO1 depletions argues that they participate in 
alternative pathways for repair of cisplatin damage. In a second 
experiment, cells were exposed to chronic, low-level cisplatin 
than pso2 or dna2–1 single mutants, consistent with a role for 
DNA2 in the repair of ICL in yeast (Fig. S3).
In human cells, the single DNA2 or EXO1 depletions were 
not significantly more sensitive to acute cisplatin treatment than 
the controls, but the doubly depleted cells showed marked hyper-
sensitivity to cisplatin at 0.6 μM, a low concentration, chosen 
Figure 7. DNA2 and eXO1 are required for survival after exposure to Cisplatin but do not increase Cisplatin sensitivity of FANCD2-deficient cells. 
(A) Clonogenic assay of survival of DNA2- and/or eXO1-depleted cells exposed to cisplatin for 24 h. (B) Survival of DNA2-depleted cells exposed to cis-
platin for 6 d. (C) PD20 cells with DNA2 and/or eXO1-depletion or PD20 cells complemented with FANCD2 were exposed to cisplatin (24 h) and assayed 
for survival. (D and E) Survival of DNA2 and/or eXO1-depleted cells exposed to CPT (1 h) or MMS (1 h) and assayed for survival. error bars indicate mean 
± SeM for n ≥ 4 independent experiments. *p < 0.05. See experimental Procedures for details. CDDP, cisplatin.
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that DNA2 functions in checkpoint activation (see model in 
Fig. S1E). This extends genetic studies implicating HDR pro-
teins in ICL repair and recent elegant mechanistic studies show-
ing ICL to be RAD51-dependent and to involve sister chromatid 
exchange, which presumably requires resection of a double-
strand end for strand invasion.9 Importantly, we demonstrated 
interaction between DNA2 and the central regulatory protein 
in the FA/BRCA pathway, FANCD2, physically linking DNA2 
to ICL repair, and showed that FANCD2-DNA2-EXO1 triply 
deficient cells are not more sensitive to ICLs than FANCD2 
mutants, suggesting function in the same pathway and action on 
the same substrates. DNA2 likely acts downstream of FANCD2, 
consistent with a role in resection of the DSB that occurs after 
unhooking of the crosslink.9 DNA2 is likely to act upstream of 
BRCA2, since DNA2 stimulates SSA, an HDR pathway inhib-
ited by BRCA2. Although FA deficiency is most prominently 
linked to ICL repair defects, the FA pathway clearly deals with 
a wide range of endogenous and exogenous template blocks that 
cause replication fork stalling. In viewing the FA pathway as a 
general response to replication fork stalling, our study answers 
a question left open by our recent studies of the role of human 
DNA2 in DNA replication. We did not find a defect in Okazaki 
fragment processing in DNA2-deficient cells, as we had in yeast. 
Yet we found accumulation of DSBs, as shown in the untreated 
(as well as CPT-treated cells in Fig. 4) DNA2-depleted cells, and 
an increase in γH2AX and RAD51 foci as well as Chk1 activa-
tion.18 In addition, we found that forks moved at normal rates 
but the cell cycle was delayed in G
2
 by the checkpoint, and that 
this is due to depressed replication origin firing, which is known 
to lead to fork collapse, for instance, in already origin-depleted 
regions such as common fragile sites.18,21 Linking DNA2 to the 
FA/BRCA pathway supports a role for DNA2 during S and G
2
 
in repair of stalled and/or collapsed forks, even in the absence 
of exogenous DNA damage. DNA2 may have evolved a more 
important role in post-replication repair in human, or our assays 
for ssDNA breaks during S phase in DNA2 knockdowns, i.e., 
alkaline comet assays during BrdU pulse-labeling protocols, may 
not have been sensitive enough to detect damage only in a subset 
of Okazaki fragments.18
A second important implication of our work is that it is likely 
consistent with our in vitro reconstitution studies,14 that DNA2 
is the nuclease that functions with BLM helicase in parallel to the 
EXO1 pathway in DSB repair.16 Presumably depletion of BLM 
incapacitates DNA2 function by depriving it of its substrate, 
BLM-helicase unwound 5’ssDNA, just as occurs in vitro.14,16
A third aspect of our work went beyond DNA2 and investi-
gated the full complement of proteins involved in resection by 
studying not just DNA2 but also EXO1. To a large extent, we 
find that the DNA2 pathway is redundant with and parallel to 
resection by EXO1, as evidenced by the synergistic drug sensi-
tivity and defects in resection in response to double depletions. 
However, several of our results also suggest more prominent 
functions for DNA2 than EXO1, as in yeast, such as in removal 
of ICLs (Figs. 2 and 7). The single DNA2 depletion showed 
reduced RPA and Chk1 phosphorylation, while EXO1 silencing 
did not, and double depletion showed only a marginal, if any, 
treatment (1, 2, 4 μM for 6 d). DNA2 knockdowns showed 
hypersensitivity even in the presence of EXO1 (Fig. 7B). This 
result may also be suggested by the results shown in Figure 7A, 
compare shDNA2 to shSCR-depleted cells, and is consistent with 
RPA and Chk1 phosphorylation deficiency results in Figure 2A, 
lanes 6 and 8.
We then examined if DNA2 and or EXO1 appeared to 
affect the FA/BRCA repair pathway. We depleted DNA2 and/
or EXO1 in FANCD2-deficient PD20 cells and performed cis-
platin sensitivity studies. As shown in Figure 7C, neither doubly 
(FANCD2/DNA2 or FANCD2/EXO1) nor triply (FANCD2/
DNA2/EXO1) depleted cells were significantly more sensitive 
to acute exposure than FANCD2-deficient cells, suggesting that 
DNA2/EXO1 and FANCD2 are in the same ICL repair path-
way. In fact, there was an increase (p < 0.05) in resistance to 
cisplatin in the DNA2/FANCD2 doubly deficient cells. This 
could be explained by an increase in NHEJ or some other repair 
pathway in the absence of DNA2 resection or to the accumu-
lation of toxic recombination intermediates if DNA2-mediated 
repair is active in the absence of FANCD2. Since DNA2/EXO1 
depletion causes significant sensitivity to cisplatin, but doesn’t 
increase ICL sensitivity in FANCD2-deficient PD20 cells, and 
because, as shown in Figure 5, DNA2 depletion does not further 
affect HDR in FANCD2-deficient PD20 cells, it is possible that 
DNA2/EXO1 and FANCD2 act in the same pathway, act coor-
dinately or that FANCD2 is upstream of DNA2/EXO1.
Since endogenous replication-associated damage is likely not 
due to crosslinks, but to general replication fork failure, we also 
examined hypersensitivity to CPT and MMS. We observed that 
resistance to CPT was significantly diminished in cells with 
DNA2/EXO1 double depletion compared with the respective 
single depletions (Fig. 7D). This is consistent with the obser-
vation that BLM/EXO1 doubly depleted cells are significantly 
more sensitive to CPT than BLM or EXO1 single depletions.16
MMS is a DNA methylating agent that predominantly forms 
N7-methylguanine adducts postulated to be converted to DSBs 
during replication49,50 and are repaired by HDR.50,51 When DNA2 
and EXO1 were simultaneously depleted, we saw a synergistic 
response in MMS sensitivity, with the double depletions being 
more sensitive than the single depletions. A distinct hierarchy of 
sensitivity was apparent. DNA2-depleted cells were more sensi-
tive than EXO1-depleted cells or the scrambled control, meaning 
that DNA2 can compensate for the loss of EXO1, but EXO1 
cannot compensate for the loss of DNA2 (Fig. 7E). We conclude 
that, while DNA2 and EXO1 may function in independent path-
ways, these pathways may be partially redundant for repair of 
MMS-induced DNA damage.
Discussion
In our study, we established a role for human DNA2 in resection 
of DSBs, especially those occurring during repair of replication 
forks stalled by ICLs. This work provides in vivo confirmation 
that resection pathways are conserved from yeast to man, previ-
ously suggested, but not proved, by our in vitro reconstitution 
studies52 and extends a report by others.15 We also discovered 
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interesting to investigate whether DNA2 can be used to identify 
more genes specifically interacting with the FA/BRCA pathway 
that may serve as markers for these diseases in earlier stages than 
is now possible.
Experimental Procedures
Cell culture and transfections. U2OS, U2OS-DR-GFP (Pierce, 
1999) and U2OS-SA-GFP (Gunn, 2011) cells were gifts from Dr. 
W. Dunphy, California Institute of Technology; Dr. M. Jasin, 
Memorial Sloan-Kettering Cancer Center and Dr. J. Stark, City 
of Hope. PD20 fancD2-/- lines were from the Fanconi Anemia 
Research Fund. Cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% heat-inactivated fetal 




Virus production and infection. Virus was produced in 
HEK293T cells as described.17,58 Briefly, cells were transfected 
with pLKO.1 shSCR, pLKO.1 shDna2 or pRESQ shDna2' and 
pCMVΔR8.2 and pCMV-VSV-G (the latter two at 8:1 ratio) using 
BioT (Bioland Scientific). Virus was recovered 48 h post-transfec-
tion and infections were performed on U2OS cells overnight in 
the presence of 10 μg/ml of protamine sulfate. Transduced cells 
were selected with 2 μg/ml of puromycin for 48 h. The following 
sequences were used for the hDna2 short hairpins, 5'-CAT AGC 
CAG TAG TAT TCG ATG-3' for shDna2, 5'-GCA GTA TCT 
CCT CTA GCT AGT for pRESQ shDna2' and 5'-AAG GTT 
AAG TCG CCC TCG CTC-3' for shSCR.17,18
For depletion of EXO1, siRNA duplexes, purchased from 
Dharmacon, were transfected into cells using oligofectamine 
(Life Technologies). siRNA sequences are as follows, siCNTL 
(luciferase 5'-CGU ACG CGG AAU ACU UCG ATT-3') 
and siEXO1 (5'-CAA GCC UAU UCU CGU AUU UTT-3') 
(Gravel, 2008). Depletion of DNA2 and EXO1 was determined 
by Taqman qualitative PCR (Qiagen). Experiments were per-
formed 48 h post-siRNA transfection.
Knockdown rescue experiment. For complementation stud-
ies, virus was produced as described above using plasmids, pBabe-
Hygro-3xFlag-DNA2, pRESQ shSCR and pRESQ shDna2'.17,18 
U2OS cells overexpressing FLAG-tagged DNA2 were selected in 
200 μg/ml hygromycin for 5 d and then transduced with the 
virus-containing pRESQ shSCR or pRESQ shDna2', which 
targets the 3'UTR of endogenous DNA2 but not the exogenous 
DNA2, and selected with 2 μg/ml of puromycin for 48 h.18 Cells 
were then treated with control siCNTL or siEXO1 for 48 h, 
exposed to CPT (1 μM, 1 h) or cisplatin (15 μM, 24 h), or no 
damaging agent and harvested and assayed for RPA2 pS4/S8, 
pS33 and Chk1 pS345 by western blotting.
Clonogenic and cytotoxicity assays. Survival data for methyl 
methane sulfonate (MMS) and PD20 cells treated with cisplatin 
(CDDP) was generated from a cytotoxicity assay and for camp-
tothecin (CPT) or cisplatin from a clonogenic assay. Briefly, 48 h 
after depletion of DNA2 and/or EXO1, cells were serial diluted 
in media and inoculated into 12 well plates, left to attach over-
night and treated with MMS (0, 0.02, 0.03, 0.04, 0.05%) or 
CPT (0, 0.001, 0.01, 0.1 μM) for 1 h and cisplatin (0, 0.625, 
increase in RPA and Chk1 phosphorylation. DNA2 depletion 
also had a greater effect than EXO1 depletion when accumula-
tion of unrepaired breaks was studied (Fig. 4A). This further 
suggests that DNA2 and EXO1 cannot completely compensate 
for the absence of the other and that they therefore do not define 
completely redundant pathways. It may suggest that DNA2 and 
EXO1 actually act together in one resection pathway on the same 
molecules, rather than acting in compensating ways, or that they 
act in independent pathways for different types of damage. This 
is consistent with findings in the in vitro reconstituted reaction, 
where there is clearly a pathway involving both DNA2 and EXO1 
acting on the same molecule.14 It is also consistent with results 
reported in yeast.53
A fourth important finding relates to the roles of DNA2 and 
EXO1 in mediating HDR. DNA2 depletion decreased SSA, 
leading to an increase in gene conversion (Fig. 5). DNA2 associ-
ates with a DSB and at least one role of DNA2 is downstream of 
(or in parallel with) FANCD2’s role in HDR (Fig. 5).
DNA2 and EXO1 also influence the frequency of HDR vs. 
NHEJ. The HDR pathway preferentially repairs DSBs that occur 
during S- and G
2
-phase of the cell cycle. This optimizes precise 
repair of the breaks and error-free restart of replication forks. It 
has been proposed that interfering with the HDR resection path-
way facilitates genome instability and that this is mediated by the 
activation of NHEJ pathway during S-phase. Supporting this, 
deletion of CtIP results in an increase in NHEJ.25 Double deple-
tion of CtIP and EXO1 in CPT-treated cells results in an increase 
in DNA-PKcs autophosphorylation at serine 2056 and increase 
in genome rearrangements.54 The identification of the redundant 
DNA2 and EXO1 pathways allowed us to determine if inhibiting 
the long-range resection pathway alone also led to activation of 
NHEJ, i.e., even in the presence of CtIP and active short-range 
resection. Phosphorylation of DNA-PKcs in the doubly depleted 
cells treated with CPT suggests that this is the case. Importantly, 
in the case of cisplatin-treated cells we did not observe any signifi-
cant increase in DNA-PKcs hyperphosphorylation. We attribute 
this observation to FANCD2 preventing aberrant NHEJ during 
ICL repair by inhibiting DNA-PKcs phosphorylation.47
DNA2 has been linked to protecting replication forks from col-
lapse at replication fork barriers such as the ribosomal replication 
fork barrier in S. cerevisiae,55,56 and recently in Schizosaccharomyces 
pombe.41 Our results could also be explained by a role for DNA2 
in protecting forks in human cells. New roles of BRCA2 and 
stabilization of RAD51 filaments in protection of stalled replica-
tion forks, rather than repair, already provide evidence for such 
a pathway.37-39,57 Interestingly, RAD51 also associates with forks 
stalled at ICLs before the initial repair incisions.9 The linkage of 
DNA2 to the FA/BRCA pathway is also particularly interesting 
in view of recent results suggesting that DNA2 is overproduced 
in response to a specific type of replicative stress caused by induc-
tion of oncogenes such as RAS.15 DNA2 overproduction was also 
observed in cells undergoing the early stages of transformation of 
normal epithelial cells into breast tumor cells.15 A similar pattern 
was found for ovarian and pancreatic cells undergoing evolution 
to full transformation. Finally, an inverse correlation between 
breast tumor grade and level of DNA2 was established. It will be 
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1.25, 2.5 μM) for 24 h, washed and cultured. For chronic expo-
sure, cells were treated for 6 d with 0, 1, 2, 4 μM cisplatin. For 
susceptibility to MMS, and cisplatin (for PD20 cells) 48 h post-
treatment, cells were fixed and stained with 1% crystal violet in 
methanol and viability count determined by imaging cell density 
using near infrared imaging (Li-Cor). For CPT and cisplatin, 
colonies were allowed to form for 14 d prior to fixation, staining 
with crystal violet and enumeration of visible colonies.
Immunofluoresence microscopy. This was performed essen-
tially as described (Duxin, 2009). Details can be found in 
Supplemental Materials.
Recombination assay. DNA2 was depleted from DR-GFP or 
SA-GFP cells. Cells were transfected with an empty plasmid or a 
plasmid-expressing I-SceI endonuclease for 48 h. GFP+ cells were 
determined by flow cytometry.
Statistical analysis. Student’s t-tests were performed at 
p < 0.05.
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